Clinical and Humanistic Outcomes in Patients With Gastroesophageal Reflux Disease Converted From Omeprazole to Lansoprazole

Nelson, Winnie W.; Vermeulen, Lee C.; Geurkink, Eric; Ehlert, David A.; Reichelderfer, Mark

doi:10.1001/archinte.160.16.2491

Cited by 34 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been our anecdotal experience that with each antisecretory drug substitution program performed at our hospital (e.g., cimetidine to ranitidine, ranitidine to nizatidine, omeprazole to lansoprazole [LAN], LAN to rabeprazole [RAB]), some of our patients have complained that the new drug was less effective and have requested to be switched back. This experience is similar to that reported by other hospitals [4][5][6][7]. For example, at the Palo Alto VA hospital, approximately 10% of veterans who were switched from omeprazole to LAN were subsequently switched back.…”

Section: Introductionsupporting

confidence: 84%

Failures in a Proton Pump Inhibitor Therapeutic Substitution Program: Lessons Learned

Malladi

Agha

et al. 2007

Dig Dis Sci

View full text Add to dashboard Cite

The pathogenesis of patient dissatisfaction following involuntary therapeutic substitutions involving proton pump inhibitors (PPIs) is poorly understood. The aim of this study was to describe the patient population experiencing therapeutic failure and investigate whether failure was related to individual differences in response to the different PPIs. Treatment failures in a lansoprazole-rabeprazole therapeutic substitution program were compared to switch successes. A subgroup was randomized in a double-blind, double-dummy, crossover study to four 2-week periods of lansoprazole-rabeprazole-lansoprazole-rabeprazole or vice versa. Measures included overall rating of gastrointestinal reflux disease (GERD) symptoms for the past week as well as the frequency and distress scales of the GERD Symptom Assessment Scale. One hundred fifteen nonresponders were compared with 54 successful responders. Nonresponders consisted primarily of patients with GERD (74%, vs. 44% of responders; P = 0.005) who had undergone upper gastrointestinal endoscopy (50%, vs. 31% of responders; P = 0.02). Twelve patients completed the randomized treatment study. The interrater kappa coefficient for responder status was estimated to be 0.80 for lansoprazole and 0.21 for rabeprazole. The majority of PPI nonresponders had a clinical diagnosis of GERD and were receiving >/=40 mg of rabeprazole daily. This pilot study provides new insights into the design of subsequent studies of nonresponders in PPI therapeutic substitution programs.

show abstract

Section: Introductionsupporting

confidence: 84%

Failures in a Proton Pump Inhibitor Therapeutic Substitution Program: Lessons Learned

Malladi

Agha

et al. 2007

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…17 Although some clinicians may challenge the clinical equivalence and therapeutic substitution of PPIs, [18][19][20][21] all drugs within this therapeutic category are known to be effective in both healing ulcerations and alleviating the symptoms of reflux. 22,23 The American Society of HealthSystem Pharmacists (ASHP) promulgated national guidelines for SUP in 1999.…”

Section: ■■ Discussionmentioning

confidence: 99%

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Thomas

Culley²,

Gladowski³

et al. 2010

JMCP

View full text Add to dashboard Cite

show abstract

“…Research with 2 medications from a different class of drugs also with no significant differences in efficacy or safety found that about half of the patients converted from omeprazole to lansoprazole reported worsening symptoms of heartburn. 20 Nearly half of the subjects (47%) in our study who initiated conversion were successfully converted from sumatriptan to rizatriptan ODT. This result was accomplished without change in the number or cost of migraine-related office visits.…”

Section: Assessment Of Clinical Service and Cost Outcomes Of A Convmentioning

confidence: 80%

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches

Gershovich¹,

Billups²,

Delate³

et al. 2006

JMCP

View full text Add to dashboard Cite

It is estimated that 6% of men and 18% of women in the United States suffer from migraine headaches. Approximately 10% of primary care office visits are for headaches, with the majority being for migraines.1 The impact of migraine headaches on pain, disability, and general health results in a significant financial burden as it is estimated that the U.S. spends $14 billion annually on migraine treatment, including missed workdays and associated loss of productivity.

show abstract

Clinical and Humanistic Outcomes in Patients With Gastroesophageal Reflux Disease Converted From Omeprazole to Lansoprazole

Cited by 34 publications

References 13 publications

Failures in a Proton Pump Inhibitor Therapeutic Substitution Program: Lessons Learned

Failures in a Proton Pump Inhibitor Therapeutic Substitution Program: Lessons Learned

Longitudinal Analysis of the Costs Associated with Inpatient Initiation and Subsequent Outpatient Continuation of Proton Pump Inhibitor Therapy for Stress Ulcer Prophylaxis in a Large Managed Care Organization

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches

Contact Info

Product

Resources

About